Last reviewed · How we verify
inhaled Ambisome®
Amphotericin B, the active component of Ambisome, binds to the sterol component of fungal cell membranes, causing cell lysis and death.
Amphotericin B, the active component of Ambisome, binds to the sterol component of fungal cell membranes, causing cell lysis and death. Used for Treatment of invasive aspergillosis, candidemia, and other serious fungal infections.
At a glance
| Generic name | inhaled Ambisome® |
|---|---|
| Sponsor | Poitiers University Hospital |
| Drug class | Polyene antifungal |
| Target | Sterol component of fungal cell membranes |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
This process is known as a 'pore-forming' mechanism, where the drug inserts itself into the cell membrane, disrupting its integrity and leading to cell death. The exact mechanism is not fully understood, but it is thought to involve the formation of pores in the cell membrane, allowing ions and water to flow in and out of the cell, ultimately leading to cell lysis.
Approved indications
- Treatment of invasive aspergillosis, candidemia, and other serious fungal infections
Common side effects
- Nausea
- Vomiting
- Abdominal pain
- Diarrhea
- Headache
- Fatigue
- Rash
- Hypotension
- Anaphylaxis
Key clinical trials
- Chronic Pulmonary Aspergillosis and Ambisome Aerosol with Itraconazole (PHASE3)
- Factors on Therapeutic Drug Monitoring and Safety of Voriconazole in Critically Ill Elderly Patients
- An Individualized Administration Research of Voriconazole Based on CYP2C19 Gene Polymorphism and TDM
- Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia (PHASE2)
- Safety and Efficacy Study of Inhaled AmBisome for Prevention of Aspergillus Colonization in Lung Transplant Recipients (PHASE2)
- Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®) (PHASE3)
- Abelcet Radiotagging Protocol: Inhaled Lipid Complex Abelcet® in Lung Transplant Recipients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- inhaled Ambisome® CI brief — competitive landscape report
- inhaled Ambisome® updates RSS · CI watch RSS
- Poitiers University Hospital portfolio CI